



## PRESS RELEASE

### Leading European Manufacturers found EMMA

*The Pan-European Consortium of PET Radiopharmaceutical Manufacturers will consolidate the development and the diffusion of new PET drugs across Europe*

**Saint Genis Pouilly, France (April 23<sup>rd</sup>, 2010)** – Advanced Accelerator Applications (AAA), Biokosmos, Erigal, Map Medical and PET Net Solutions, five prominent European radiopharmaceutical manufacturers, have today announced the creation of EMMA (European Molecular Imaging Manufacturers Association), a consortium of private sector entities that has pooled its resources, comprising some 16 production facilities, to respond to various developments in the Positron Emission Tomography (PET) pharmaceutical industry.

EMMA will take full advantage of the enterprise and spirit of the European Union in developing the necessary scope and breadth of representation to become truly “trans-national”. This unique European solution will also fill the short-term need of supporting new PET tracer compounds that are currently in the last phases of clinical research and will soon become valuable products in the fields of Oncology, Cardiology and Neurology.

The **major objectives** of the consortium are:

- to present a cohesive response to those seeking a Europe-wide manufacturing and distribution capability for their PET tracers, predominantly Fluorine-18 labelled radiopharmaceuticals;
- to provide constructive advice and uniform direction to key stakeholders in the vertical chain of PET Imaging Service Provision in both public and private sectors across Europe.

Explaining the rationale behind this innovative initiative, Stefano Buono, President and CEO of Advanced Accelerator Applications (a founding partner of the consortium) stated: “This venture addresses the urgent need to bring together a heightened focus in what has historically been a notoriously fragmented industry”. More than a “consolidation move”, Buono emphasized that “this is a strategic reinforcement of our companies’ common strengths to profit from their respective leadership into their complementary geographical markets. This partnership will inject new vitality into what portends to be a high-growth business for the sustainable future”. “For the first time”, Stefano Buono added, “viable EU producers will be able to manufacture on a large enough scale to develop and promote profitable, new PET drugs into the European market using common equipment and standards within a coordinated network thus solving the traditional “complexity” associated with the short shelf life of PET tracers.

EMMA’s members will initially include **Advanced Accelerators Applications SA** (“AAA”) – with laboratories in France, Italy, Switzerland and Spain, **Biokosmos SA** – Greece, **Erigal Ltd.** - Ireland and the UK, **Map Medical Technologies Oy** – Finland, **PET Net Solutions AG** – with 2 laboratories in Germany. Because of the anticipated positive impact that this consortium will have on the European PET market, it is envisaged that future additional partners will be invited to join.



MAP MEDICAL  
TECHNOLOGIES



The consortium will have one of its members acting as its representative to third parties on a revolving basis. AAA has been appointed at this role for the first 3 years.

## **Note to Editors**

### **About PET**

A PET scan is a non-invasive medical imaging technology, which provides a unique window on the physiology and function of living organisms. Today it allows precise staging of tumors and localisation of metastases into the patient's body. It is also capable of evaluating the individual response to a specific cancer therapy and improves treatment monitoring. The pharmaceutical products injected to the patient have nevertheless a shelf life of only 10-12 hours so they must be produced daily in facilities that are located very near to the end user.

### **About Advanced Accelerator Applications (AAA, [www.adacap.com](http://www.adacap.com))**

Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 to develop innovative diagnostic and therapeutic applications and products. AAA's main research focus is in the field of Molecular Imaging and Therapy for personalized treatment of serious diseases (the so-called Personalised Medicine). AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. AAA currently has 10 production and R&D facilities in four countries (France, Italy, Switzerland and Spain), more than 130 employees and approximately € 25 million in annual turnover.

### **About Biokosmos ([www.biokosmos.gr](http://www.biokosmos.gr))**

Biokosmos, is a Greek company founded in 1992 with the purpose to provide high quality solutions to the Greek Medical Community in the field of oncology through its state-of-the-art facilities and its high quality services. Biokosmos is a leading company in the field of radiotherapy systems and solutions and in the immunology analyzers (RIA and CLIA). In June 2004 Biokosmos installed and operated in Greece the first cyclotron for the production of PET radiopharmaceuticals. This marked a new era for the Greek Medical Community as it enabled the installation of PET/CT systems. Biokosmos has today more than 40 employees and approximately € 11 million in annual turnover.

### **About Erigal ([www.erigal.co.uk](http://www.erigal.co.uk))**

Erigal has its origins in a joint venture arrangement between M2i Holdings – founders of a radiopharmaceutical production facility in Ireland in year 2000 - and Alliance Medical Limited – a pan-European private sector provider of patient imaging services. In 2003 both organisations forged a partnership to establish a reliable supply of PET radiopharmaceuticals to promote the development of PET/CT scanning in front-line medical imaging in the UK. Erigal has designed, built, licensed and now manages a network of four Radiopharmaceutical Production Units (RPU) at Dublin, Keele, Preston and at the Royal Marsden Hospital (RMH) London, to provide an unrivalled capability to support the growth of PET in the region. Its 40 personnel support the current production output, generating a turnover of circa €8 million together with a newly established Management Services division.



**Erigal**



**MAP MEDICAL  
TECHNOLOGIES**



### **About Map Medical Technologies ([www.mapmedical.fi](http://www.mapmedical.fi))**

MAP Medical Technologies Oy, founded in 1991, is an independent Finnish radiopharmaceutical manufacturer. The mission of MAP is to develop, produce and distribute radiopharmaceuticals to improve the quality and length of human life. MAP's highly devoted team and modern production facilities offer a unique setting for production of high quality pharmaceuticals. Main areas in the radiopharmaceutical business are:

- Manufacture generic radiopharmaceuticals like Mo-99/Tc-99m generator, iodine capsules for therapy and diagnosis, FDG and other products.
- Find and develop new diagnostic radiopharmaceuticals with scientific partners.
- MAP has also a long and successful history working as a contract manufacturer of radiopharmaceuticals.

MAP has three production sites in Finland with 30 employees. Turnover last year was € 4,3 million.

### **About PET Net ([www.pns-ag.de](http://www.pns-ag.de))**

PET Net Solutions AG was founded by Prof. Dr. Willi Kalender in 2008 as the sales and logistic arm for PET Net's two production units. The PET biomarker production units are located in Erlangen and Regensburg and are operated in close cooperation with the University in Erlangen and the University Hospital Regensburg. PET Net owns a European Market Authorization for [18F]FDG-ERL, is very active in developing and commercializing new PET biomarkers and has already started the marketing authorization process for several new compounds. PET Net owns an innovative Quality Management System and provides Consulting Services in this area. With 20 employees PET Net is expecting a turnover of more than € 4 million in 2010.

### **Contacts of EMMA representative**

#### **Advanced Accelerator Applications**

Véronique Mermet

Tel: +33 4 50 99 30 70

20 rue Diesel, 01630 Saint Genis Pouilly, France